Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
GSK’s Stevenage site set to become science campus
by Alex Scott
July 23, 2021
| A version of this story appeared in
Volume 99, Issue 27
GlaxoSmithKline aims to sell almost one-third of its 370,000 m2 R&D site in Stevenage, England, so that the land can be transformed into a biotech science campus. GSK says the plan could unlock up to $470 million of private investment and create up to 5,000 skilled jobs this decade. GSK hopes detailed planning for the campus will begin in 2022. A number of other organizations are already at the site, including the UK government’s Cell and Gene Therapy Catapult and some biotech start-ups.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X